Bausch + Lomb Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
15:40
Apr 30
Apr 30
Strong execution, expanding margins, durable growth.
Bausch + Lomb has achieved durable sales growth over three years, expanded margins (EBITDA +59%), and has a strong R&D pipeline of 60+ programs, indicating solid execution and future potential.
MED
01:02
Jan 13
Jan 13
Bausch + Lomb pipeline targets growth.
Saunders says Bausch + Lomb has its deepest pipeline in 172 years, including a bioactive contact lens that is the first major lens innovation in 25 years, a phase 2 glaucoma asset that improves vision, Lumify innovation, and dry eye/ocular pain products. The investor day plan targets fastest-growing eye care company with 600 basis points of margin improvement and he is confident in delivering the numbers.
HIGH
About Bausch + Lomb Investor Commentary
Across the available history and selected sources, Buzzberg tracks Bausch + Lomb across 1 sources: 2 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Brent Saunders.